{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:38:31Z","timestamp":1771677511740,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00393-024-01611-x","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T09:55:17Z","timestamp":1737712517000},"page":"48-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["\u201eT-large granular lymphocytic\u201c-Leuk\u00e4mie und Felty-Syndrom bei rheumatoider Arthritis","T-cell large granular lymphocytic leukemia and Felty\u2019s syndrome in rheumatoid arthritis"],"prefix":"10.1007","volume":"84","author":[{"given":"Michael","family":"Gernert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva Christina","family":"Schwaneck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Schmalzing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"4","key":"1611_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00393-022-01192-7","volume":"81","author":"K Albrecht","year":"2022","unstructured":"Albrecht\u00a0K, Callhoff\u00a0J, Strangfeld\u00a0A (2022) Steigt die Pr\u00e4valenz der rheumatoiden Arthritis wirklich an? Z\u00a0Rheumatol 81(4):323\u2013327. https:\/\/doi.org\/10.1007\/s00393-022-01192-7","journal-title":"Z Rheumatol"},{"key":"1611_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1055\/s-0035-1569281","volume":"41","author":"EC Scharbatke","year":"2016","unstructured":"Scharbatke\u00a0EC, Junker\u00a0L, Gadeholt\u00a0O, Tony\u00a0H\u2011P, Schmalzing\u00a0M (2016) Felty-Syndrom und T\u2011LGL-Leuk\u00e4mie bei Rheumatoider Arthritis. Wann muss man daran denken? Akt Rheumatol 41:157\u2013161","journal-title":"Akt Rheumatol"},{"issue":"6","key":"1611_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/s0167-5699(99)01472-3","volume":"20","author":"MK Maini","year":"1999","unstructured":"Maini\u00a0MK, Casorati\u00a0G, Dellabona\u00a0P, Wack\u00a0A, Beverley\u00a0PC (1999) T\u2011cell clonality in immune responses. Immunol Today 20(6):262\u2013266. https:\/\/doi.org\/10.1016\/s0167-5699(99)01472-3","journal-title":"Immunol Today"},{"issue":"3","key":"1611_CR4","doi-asserted-by":"publisher","first-page":"B196","DOI":"10.1093\/gerona\/53a.3.b196","volume":"53","author":"NS Ricalton","year":"1998","unstructured":"Ricalton\u00a0NS, Roberton\u00a0C, Norris\u00a0JM, Rewers\u00a0M, Hamman\u00a0RF, Kotzin\u00a0BL (1998) Prevalence of CD8+ T\u2011cell expansions in relation to age in healthy individuals. J\u00a0Gerontol A Biol Sci Med Sci 53(3):B196\u2013203. https:\/\/doi.org\/10.1093\/gerona\/53a.3.b196","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6","key":"1611_CR5","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/ijlh.13949","volume":"44","author":"B Chin-Yee","year":"2022","unstructured":"Chin-Yee\u00a0B, Suthakaran\u00a0A, Hedley\u00a0BD, Howlett\u00a0C, Stuart\u00a0A, Sadikovic\u00a0B et\u00a0al (2022) T\u2011cell clonality testing for the diagnosis of T\u2011cell large granular lymphocytic leukemia: are we identifying pathology or incidental clones? Int J Lab Hematol 44(6):1115\u20131120. https:\/\/doi.org\/10.1111\/ijlh.13949","journal-title":"Int J Lab Hematol"},{"issue":"5","key":"1611_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00393-005-0013-4","volume":"65","author":"F Moosig","year":"2006","unstructured":"Moosig\u00a0F, Schoch\u00a0R, Kneba\u00a0M (2006) Die T\u2011large Granular Lymphocyte Leuk\u00e4mie (T-LGL-Leuk\u00e4mie). Eine wichtige Differenzialdiagnose zum Felty-syndrom. Z\u00a0Rheumatol 65(5):447\u2013451. https:\/\/doi.org\/10.1007\/s00393-005-0013-4","journal-title":"Z Rheumatol"},{"key":"1611_CR7","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio\u00a0R, Amador\u00a0C, Anagnostopoulos\u00a0I et\u00a0al (2022) The 5th\u00a0edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36:1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"issue":"7","key":"1611_CR8","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3390\/cancers16071307","volume":"16","author":"F Ullah","year":"2024","unstructured":"Ullah\u00a0F, Markouli\u00a0M, Orland\u00a0M, Ogbue\u00a0O, Dima\u00a0D, Omar\u00a0N, Mustafa Ali\u00a0MK (2024) Large granular lymphocytic leukemia: clinical features, molecular pathogenesis, diagnosis and treatment. Cancers 16(7):1307","journal-title":"Cancers"},{"issue":"38","key":"1611_CR9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/EDBK_200689","volume":"23","author":"A Moignet","year":"2018","unstructured":"Moignet\u00a0A, Lamy\u00a0T (2018) Latest advances in the diagnosis and treatment of large granular lymphocytic leukemia. Am Soc Clin Oncol Educ Book 23(38):616\u2013625. https:\/\/doi.org\/10.1200\/EDBK_200689","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1611_CR10","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1182\/blood.V95.10.3219","volume":"95","author":"JH Liu","year":"2000","unstructured":"Liu\u00a0JH, Wie\u00a0S, Lamy\u00a0T, Epling-Burnette\u00a0PK, Starkebaum\u00a0G, Djeu\u00a0JY et\u00a0al (2000) Chronic neutropenia mediated by Fas ligand. Blood 95:3219\u20133222","journal-title":"Blood"},{"issue":"3","key":"1611_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/s0037-1963(03)00133-1","volume":"40","author":"T Lamy","year":"2003","unstructured":"Lamy\u00a0T, Loughran\u00a0TP Jr. (2003) Clinical features of large granular lymphocyte leukemia. Semin Hematol 40(3):185\u2013195. https:\/\/doi.org\/10.1016\/s0037-1963(03)00133-1","journal-title":"Semin Hematol"},{"issue":"S1","key":"1611_CR12","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.5045\/br.2023.2023037","volume":"58","author":"SH Park","year":"2023","unstructured":"Park\u00a0SH, Lee\u00a0YJ, Kim\u00a0Y, Kim\u00a0HK, Lim\u00a0JH, Jo\u00a0JC (2023) T\u2011large granular lymphocytic leukemia. Blood Res 58(S1):S52\u2013S57. https:\/\/doi.org\/10.5045\/br.2023.2023037","journal-title":"Blood Res"},{"issue":"9","key":"1611_CR13","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3324\/haematol.2009.018481","volume":"95","author":"B Bareau","year":"2010","unstructured":"Bareau\u00a0B, Rey\u00a0J, Hamidou\u00a0M, Donadieu\u00a0J, Morcet\u00a0J, Reman\u00a0O, Schleinitz\u00a0N, Tournilhac\u00a0O, Roussel\u00a0M, Fest\u00a0T, Lamy\u00a0T (2010) Analysis of a\u00a0French cohort of patients with large granular lymphocyte leukemia: a\u00a0report on 229 cases. Haematologica 95(9):1534\u20131541. https:\/\/doi.org\/10.3324\/haematol.2009.018481","journal-title":"Haematologica"},{"issue":"10","key":"1611_CR14","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1182\/blood-2010-07-296962","volume":"117","author":"T Lamy","year":"2011","unstructured":"Lamy\u00a0T, Loughran\u00a0TP Jr (2011) How I treat LGL leukemia. Blood 117(10):2764\u20132774. https:\/\/doi.org\/10.1182\/blood-2010-07-296962","journal-title":"Blood"},{"issue":"3","key":"1611_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1634\/theoncologist.9-3-247","volume":"9","author":"MG Rose","year":"2004","unstructured":"Rose\u00a0MG, Berliner\u00a0N (2004) T\u2011cell large granular lymphocyte leukemia and related disorders. Oncologist 9(3):247\u2013258. https:\/\/doi.org\/10.1634\/theoncologist.9-3-247","journal-title":"Oncologist"},{"issue":"8","key":"1611_CR16","doi-asserted-by":"publisher","first-page":"e455","DOI":"10.1038\/bcj.2016.59","volume":"6","author":"MV Shah","year":"2016","unstructured":"Shah\u00a0MV, Hook\u00a0CC, Call\u00a0TG, Go\u00a0RS (2016) A\u00a0population-based study of large granular lymphocyte leukemia. Blood Cancer\u00a0J 6(8):e455. https:\/\/doi.org\/10.1038\/bcj.2016.59","journal-title":"Blood Cancer J"},{"issue":"12","key":"1611_CR17","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"JJ van Dongen","year":"2003","unstructured":"van Dongen\u00a0JJ, Langerak\u00a0AW, Br\u00fcggemann\u00a0M, Evans\u00a0PA, Hummel\u00a0M, Lavender\u00a0FL, Delabesse\u00a0E, Davi\u00a0F, Schuuring\u00a0E, Garc\u00eda-Sanz\u00a0R, van Krieken\u00a0JH, Droese\u00a0J, Gonz\u00e1lez\u00a0D, Bastard\u00a0C, White\u00a0HE, Spaargaren\u00a0M, Gonz\u00e1lez\u00a0M, Parreira\u00a0A, Smith\u00a0JL, Morgan\u00a0GJ, Kneba\u00a0M, Macintyre\u00a0EA (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T\u2011cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED\u20112 concerted action BMH4-CT98-3936. Leukemia 17(12):2257\u20132317. https:\/\/doi.org\/10.1038\/sj.leu.2403202","journal-title":"Leukemia"},{"key":"1611_CR18","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1182\/blood.V84.7.2164.2164","volume":"84","author":"TP Loughran","year":"1994","unstructured":"Loughran\u00a0TP, Kidd\u00a0PG, Starkebaum\u00a0G (1994) Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 84:2164\u20132170","journal-title":"Blood"},{"issue":"5","key":"1611_CR19","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.semarthrit.2020.05.020","volume":"50","author":"H Lobbes","year":"2020","unstructured":"Lobbes\u00a0H, Dervout\u00a0C, Toussirot\u00a0E, Felten\u00a0R, Sibilia\u00a0J, Wendling\u00a0D et\u00a0al (2020) Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a\u00a0retrospective case series. Semin Arthritis Rheum 50(5):1109\u20131113. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.05.020","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"1611_CR20","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1182\/blood-2013-03-491464","volume":"122","author":"D Cornec","year":"2013","unstructured":"Cornec\u00a0D, Devauchelle-Pensec\u00a0V, Jousse-Joulin\u00a0S, Marhadour\u00a0T, Ugo\u00a0V, Berthou\u00a0C et\u00a0al (2013) Long-term remission of T\u2011cell large granular lymphocyte leukemia associated with rheumatoid arthritis after rituximab therapy. Blood 122(9):1583\u20131586. https:\/\/doi.org\/10.1182\/blood-2013-03-491464","journal-title":"Blood"},{"issue":"4","key":"1611_CR21","first-page":"384","volume":"40","author":"A Raposo","year":"2015","unstructured":"Raposo\u00a0A, Cerqueira\u00a0M, Costa\u00a0J, Sousa Neves\u00a0J, Teixeira\u00a0F, Afonso\u00a0C (2015) Rheumatoid arthritis and associated large granular lymphocytic leukemia\u2014successful treatment with rituximab. Acta Reumatol Port 40(4):384\u2013387","journal-title":"Acta Reumatol Port"},{"issue":"3","key":"1611_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jbspin.2014.12.001","volume":"82","author":"F Verhoeven","year":"2015","unstructured":"Verhoeven\u00a0F, Guillot\u00a0X, Prati\u00a0C, Wendling\u00a0D (2015) Treatment of pseudo Felty\u2019s syndrome: Is there a\u00a0place for rituximab? Joint Bone Spine 82(3):196\u2013199. https:\/\/doi.org\/10.1016\/j.jbspin.2014.12.001","journal-title":"Joint Bone Spine"},{"issue":"12","key":"1611_CR23","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1038\/leu.2015.280","volume":"29","author":"B Bilori","year":"2015","unstructured":"Bilori\u00a0B, Thota\u00a0S, Clemente\u00a0MJ, Patel\u00a0B, Jerez\u00a0A, Afable Ii\u00a0M, Maciejewski\u00a0JP (2015) Tofacitinib as a\u00a0novel salvage therapy for refractory T\u2011cell large granular lymphocytic leukemia. Leukemia 29(12):2427\u20132429. https:\/\/doi.org\/10.1038\/leu.2015.280","journal-title":"Leukemia"},{"issue":"10","key":"1611_CR24","doi-asserted-by":"publisher","first-page":"E368","DOI":"10.1002\/ajh.26275","volume":"96","author":"A Moignet","year":"2021","unstructured":"Moignet\u00a0A, Pastoret\u00a0C, Cartron\u00a0G, Coppo\u00a0P, Lamy\u00a0T (2021) Ruxolitinib for refractory large granular lymphocyte leukemia. Am J Hematol 96(10):E368\u2013E370. https:\/\/doi.org\/10.1002\/ajh.26275","journal-title":"Am J Hematol"},{"key":"1611_CR25","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1182\/blood.V87.3.1199.bloodjournal8731199","volume":"87","author":"EP Gabor","year":"1996","unstructured":"Gabor\u00a0EP, Mishalani\u00a0S, Lee\u00a0S (1996) Rapid response to cyclosporine therapy and sustained remission in large granular lymphocyte leukemia. Blood 87:1199\u20131200","journal-title":"Blood"},{"key":"1611_CR26","first-page":"16","volume":"35","author":"AR Felty","year":"1924","unstructured":"Felty\u00a0AR (1924) Chronic arthritis in the adult associated with splenomegaly and leucopenia. Johns Hopkins Hosp Bull 35:16\u201320","journal-title":"Johns Hopkins Hosp Bull"},{"key":"1611_CR27","doi-asserted-by":"publisher","first-page":"1238405","DOI":"10.3389\/fmed.2023.1238405","volume":"10","author":"C Wegscheider","year":"2023","unstructured":"Wegscheider\u00a0C, Ferincz\u00a0V, Sch\u00f6ls\u00a0K, Maieron\u00a0A (2023) Felty\u2019s syndrome. Front Med 10:1238405. https:\/\/doi.org\/10.3389\/fmed.2023.1238405","journal-title":"Front Med"},{"issue":"6","key":"1611_CR28","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1136\/ard.36.6.500","volume":"36","author":"CW Sienknecht","year":"1977","unstructured":"Sienknecht\u00a0CW, Urowitz\u00a0MB, Pruzanski\u00a0W, Stein\u00a0HB (1977) Felty\u2019s syndrome. Clinical and serological analysis of 34\u00a0cases. Ann Rheum Dis 36(6):500\u2013507. https:\/\/doi.org\/10.1136\/ard.36.6.500","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1611_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1365-2249.1995.tb02271.x","volume":"101","author":"SJ Bowman","year":"1995","unstructured":"Bowman\u00a0SJ, Bhavnani\u00a0M, Geddes\u00a0GC, Corrigall\u00a0V, Boylston\u00a0AW, Panayi\u00a0GS, Lanchbury\u00a0JS (1995) Large granular lymphocyte expansions in patients with Felty\u2019s syndrome: analysis using anti-T\u00a0cell receptor V beta-specific monoclonal antibodies. Clin Exp Immunol 101(1):18\u201324. https:\/\/doi.org\/10.1111\/j.1365-2249.1995.tb02271.x","journal-title":"Clin Exp Immunol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01611-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01611-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01611-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T14:22:39Z","timestamp":1738160559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01611-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1611"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01611-x","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"11 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"M.\u00a0Gernert: A.\u00a0Finanzielle Interessen: Referentenhonorar: AbbVie, Eli Lilly, Janssen, Novartis. \u2013 Kongressteilnahme: AbbVie, Eli Lilly, Hexal, Janssen, Novartis, Pfizer, UCB. \u2013 Advisory-Board: Amgen, AstraZeneca, Novartis, Takeda.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Oberarzt, Medizinische Klinik\u00a02, Schwerpunkt Rheumatologie\/Klinische Immunologie, Universit\u00e4tsklinikum W\u00fcrzburg | Mitglied: Deutsche Gesellschaft f\u00fcr Rheumatologie und klinische Immunologie. M.\u00a0Schmalzing: A.\u00a0Finanzielle Interessen: Chugai, Novartis: projektbezogene Grants. \u2013 Referentenhonorar: BMS, Novartis, AbbVie, AstraZeneca, Chugai\/Roche, Janssen-Cilag, Gilead, Boehringer\/Ingelheim, Mylan, onkowissen.de, Galapagos, EUSAPharma. \u2013 Kongressteilnahme: Chugai\/Roche, Boehringer\/Ingelheim, Celgene, Medac, UCB, Mylan, Galapagos. \u2013 Advisory-Board: Chugai\/Roche, Hexal\/Sandoz, Gilead, AbbVie, Janssen-Cilag, Boehringer\/Ingelheim, onkowissen.de, EUSA-Pharma, Novartis, AstraZeneca, Amgen, medac, Lilly, Galapagos, UCB. \u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Oberarzt, Medizinische Klinik\u00a02, Schwerpunkt Rheumatologie\/Klinische Immunologie, Universit\u00e4tsklinikum W\u00fcrzburg | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Rheumatologie und klinische Immunologie, AGRZ | Vorstand: Deutsches Netzwerk Systemische Sklerodermie. E.\u00a0V.\u00a0Schwaneck: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Fresenius. \u2013 Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Janssen, Chugai, Takeda, AbbVie, Novartis, Galapagos, Alfasigma, GSK, Amgen, medac, Otsuka, UCB, Fresenius, Boehringer Ingelheim, AstraZeneca. \u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u00e4.: Novartis, medac. \u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte Gesch\u00e4ftsf\u00fchrerin MVZ Rheumatologie und Autoimmunmedizin, Hamburg | Mitgliedschaften: DGRH, BDRH, Rheumaliga.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}